Literature DB >> 7673988

A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults.

D J Stewart1, S Dahrouge, K Soltys.   

Abstract

Fourteen patients with malignant gliomas were entered on a phase II study of 5-fluorouracil 300-370 mg/m2 plus folinic acid 200 mg/m2 x 5 days q4 weeks. To be eligible, patients could not have received more than 1 prior chemotherapy regimen. A single patient with a recurrent oligodendroglioma responded. Toxicity (predominantly stomatitis, diarrhea, and granulocytopenia) was tolerable and was similar to that seen in studies of 5-fluorouracil plus folinic acid in other tumor types. This regimen has minimal activity in recurrent malignant gliomas.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7673988     DOI： 10.1007/bf01059957

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  16 in total

1.  Retrospective comparative analysis of 5FU + low-dose folinic acid vs. 5FU + high-dose folinic acid in the treatment of metastatic colorectal cancer. The Ottawa experience.

Authors:  J A Maroun; C Cripps; R Goel; S Dahrouge; D Boisvert
Journal:  Am J Clin Oncol       Date:  1997-08       Impact factor: 2.339

2.  Single versus multiple drug therapy in the combined treatment of malignant gliomas. A multicenter study.

Authors:  R Knerich; D Adinolfi; F Giunta; P Buoncristiani; P Gaetani; R Assietti; F D'Ettorre; G Butti; D Schiffer
Journal:  J Neurosurg Sci       Date:  1990 Jul-Dec       Impact factor: 2.279

3.  Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil.

Authors:  R M Evans; J D Laskin; M T Hakala
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

4.  5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung.

Authors:  W K Evans; R Wierzbicki; F A Shepherd; J Rusthoven; D J Stewart; S E Aitken; J A Maroun; A Ezzat
Journal:  Cancer Invest       Date:  1990       Impact factor: 2.176

5.  A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma.

Authors:  W R Shapiro; S B Green; P C Burger; R G Selker; J C VanGilder; J T Robertson; J Mealey; J Ransohff; M S Mahaley
Journal:  J Neurosurg       Date:  1992-05       Impact factor: 5.115

6.  BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.

Authors:  V A Levin; W F Hoffman; T L Pischer; M L Seager; E B Boldrey; C B Wilson
Journal:  Cancer Treat Rep       Date:  1978-12

7.  Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice.

Authors:  J A Houghton; S J Maroda; J O Phillips; P J Houghton
Journal:  Cancer Res       Date:  1981-01       Impact factor: 12.701

8.  Treatment of advanced breast cancer with 5-fluorouracil and high-dose folinic acid: preliminary results.

Authors:  G Marini; P Marpicati; A Zaniboni; G C Cervi; F Gorni; E Simoncini
Journal:  Chemioterapia       Date:  1985-04

Review 9.  The role of chemotherapy in the treatment of gliomas in adults.

Authors:  D J Stewart
Journal:  Cancer Treat Rev       Date:  1989-09       Impact factor: 12.111

10.  A phase II study of 5-fluorouracil plus high-dose folinic acid in the treatment of recurrent small cell lung cancer.

Authors:  D J Stewart; S Dahrouge; K M Soltys; W K Evans
Journal:  Am J Clin Oncol       Date:  1995-04       Impact factor: 2.339
View more
  4 in total

1.  Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome.

Authors:  Jessica M Grunda; John Fiveash; Cheryl A Palmer; Alan Cantor; Hassan M Fathallah-Shaykh; L Burt Nabors; Martin R Johnson
Journal:  Clin Cancer Res       Date:  2010-05-11       Impact factor: 12.531

2.  Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients.

Authors:  Jana Portnow; Timothy W Synold; Behnam Badie; Revathiswari Tirughana; Simon F Lacey; Massimo D'Apuzzo; Marianne Z Metz; Joseph Najbauer; Victoria Bedell; Tien Vo; Margarita Gutova; Paul Frankel; Mike Chen; Karen S Aboody
Journal:  Clin Cancer Res       Date:  2016-12-15       Impact factor: 12.531

Review 3.  Current perspectives in gliomas.

Authors:  C S Brock; M Bower
Journal:  Med Oncol       Date:  1997-06       Impact factor: 3.738

4.  Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses.

Authors:  Artemis P Vogazianou; Raymond Chan; L Magnus Bäcklund; Danita M Pearson; Lu Liu; Cordelia F Langford; Simon G Gregory; V Peter Collins; Koichi Ichimura
Journal:  Neuro Oncol       Date:  2010-02-17       Impact factor: 12.300
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.